A randomized phase II study of m-AMSA (NSC 249992) and neocarzinostatin (NSC 157365) in non-small cell broncliogenic carcinoma

Publisher Website
Google Scholar
Abstract
Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with m-AMSA [4''-(9-acridinylamino)-methanesulfon-m-anisidide] 120 mg/m2 i.v. every 3 wk or neocarzinostatin 2.0 mg/m2 i.v. daily .times. 5 every 4 wk. There were no responses in 40 evaluable patients who received m-AMSA and 3 partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic; for neocarzinostatin the major toxicities were hematologic, gastrointestinal and fever. Apparently, m-AMSA is inactive; neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.